Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
Wild-type Kras expands and exhausts hematopoietic stem cells
Joshua P. Sasine, … , Christopher M. Counter, John P. Chute
Joshua P. Sasine, … , Christopher M. Counter, John P. Chute
Published June 7, 2018
Citation Information: JCI Insight. 2018;3(11):e98197. https://doi.org/10.1172/jci.insight.98197.
View: Text | PDF
Research Article Hematology Stem cells

Wild-type Kras expands and exhausts hematopoietic stem cells

  • Text
  • PDF
Abstract

Oncogenic Kras expression specifically in hematopoietic stem cells (HSCs) induces a rapidly fatal myeloproliferative neoplasm in mice, suggesting that Kras signaling plays a dominant role in normal hematopoiesis. However, such a conclusion is based on expression of an oncogenic version of Kras. Hence, we sought to determine the effect of simply increasing the amount of endogenous wild-type Kras on HSC fate. To this end, we utilized a codon-optimized version of the murine Kras gene (Krasex3op) that we developed, in which silent mutations in exon 3 render the encoded mRNA more efficiently translated, leading to increased protein expression without disruption to the normal gene architecture. We found that Kras protein levels were significantly increased in bone marrow (BM) HSCs in Krasex3op/ex3op mice, demonstrating that the translation of Kras in HSCs is normally constrained by rare codons. Krasex3op/ex3op mice displayed expansion of BM HSCs, progenitor cells, and B lymphocytes, but no evidence of myeloproliferative disease or leukemia in mice followed for 12 months. BM HSCs from Krasex3op/ex3op mice demonstrated increased multilineage repopulating capacity in primary competitive transplantation assays, but secondary competitive transplants revealed exhaustion of long-term HSCs. Following total body irradiation, Krasex3op/ex3op mice displayed accelerated hematologic recovery and increased survival. Mechanistically, HSCs from Krasex3op/ex3op mice demonstrated increased proliferation at baseline, with a corresponding increase in Erk1/2 phosphorylation and cyclin-dependent kinase 4 and 6 (Cdk4/6) activation. Furthermore, both the enhanced colony-forming capacity and in vivo repopulating capacity of HSCs from Krasex3op/ex3op mice were dependent on Cdk4/6 activation. Finally, BM transplantation studies revealed that augmented Kras expression produced expansion of HSCs, progenitor cells, and B cells in a hematopoietic cell–autonomous manner, independent from effects on the BM microenvironment. This study provides fundamental demonstration of codon usage in a mammal having a biological consequence, which may speak to the importance of codon usage in mammalian biology.

Authors

Joshua P. Sasine, Heather A. Himburg, Christina M. Termini, Martina Roos, Evelyn Tran, Liman Zhao, Jenny Kan, Michelle Li, Yurun Zhang, Stéphanie C. de Barros, Dinesh S. Rao, Christopher M. Counter, John P. Chute

×

Figure 4

Increased wild-type Kras promotes hematopoietic regeneration following myelosuppression.

Options: View larger image (or click on image) Download as PowerPoint
Increased wild-type Kras promotes hematopoietic regeneration following m...
(A) Mean PB WBCs, neutrophils, lymphocytes, and platelet (Plt) counts are shown in ex3op mice and nat mice at day +14 following 750 cGy TBI (n = 10/group). *P < 0.05, **P < 0.01, ***P < 0.001. ns, non-significant. (B) Mean BM cell counts, percentage of KSL cells, and numbers of KSL cells at day +14 following 750 cGy (n = 10/group). (C) Mean numbers of BM CFCs at day +14 (n = 10/group). ***P < 0.001. (D) The percentage survival of ex3op mice and nat mice is shown through day +30 following 750 cGy TBI (n = 12/group). *P = 0.03 by log-rank test for survival analysis. For all other analyses, 2-tailed Student’s t tests were performed. Data are presented as mean ± SEM.

Copyright © 2021 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts